Abstract:ADVERTISEMENT RETURN TO ARTICLES ASAPPREVAddition/CorrectionNEXTORIGINAL ARTICLEThis notice is a correctionCorrection to “Longitudinal Serum Proteomics Characterization of CD19-CAR-T Cell Therapy for B-Cell Malignancies”Youming WangYouming WangMore by Youming Wanghttps://orcid.org/0000-0002-5797-467X, Rui SunRui SunMore by Rui Sun, Weigang GeWeigang GeMore by Weigang Ge, Lei XueLei XueMore by Lei Xue, Qianwen XuQianwen XuMore by Qianwen Xu, Hui XuHui XuMore by Hui Xu, Sujun LiSujun LiMore by Sujun Li, Miaomiao WuMiaomiao WuMore by Miaomiao Wu, Tiannan Guo*Tiannan GuoMore by Tiannan Guohttps://orcid.org/0000-0003-3869-7651, and Xingbing Wang*Xingbing WangMore by Xingbing WangCite this: J. Proteome Res. 2023, XXXX, XXX, XXX-XXXPublication Date (Web):November 2, 2023Publication History Received24 October 2023Published online2 November 2023https://doi.org/10.1021/acs.jproteome.3c00694© 2023 American Chemical SocietyRequest reuse permissions This publication is free to access through this site. Learn MoreArticle Views-Altmetric-Citations-LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InReddit PDF (678 KB) Get e-Alertsclose Get e-Alerts

Correction: Unique CDR3 Epitope Targeting by CAR-T Cells is a Viable Approach for Treating T-cell Malignancies

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Author Correction: CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia

Erratum: Evaluation of the clinicopathologic features of diffuse large B cell lymphoma after CD19-targeted CAR T-cell therapy emphasizing the potential diagnostic pitfalls.

Correction to “Longitudinal Serum Proteomics Characterization of CD19-CAR-T Cell Therapy for B-Cell Malignancies”

Correction: ROR1-targeting switchable CAR-T cells for cancer therapy

Author Correction: Decade-long leukaemia remissions with persistence of CD4 + CAR T cells

Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL

Publisher Correction: Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer

Erratum: Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study.

Corrigendum: Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells

Author Correction: A Next-Generation Tumor-Targeting IL-2 Preferentially Promotes Tumor-Infiltrating CD8+ T-cell Response and Effective Tumor Control

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer (Nature Nanotechnology, (2019), 14, 4, (388-397), 10.1038/s41565-019-0381-6)

Erratum to "Ultrasound Controllable Release of Proteolysis Targeting Chimeras for Triple-Negative Breast Cancer Treatment"

Erratum to: CAR T Cell Therapy for Hematological Malignancies

Erratum: Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.

Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China: Erratum